Fig. 3
TCRβ gene usage as a predictor of clinical response and patient survival. (A) Patients with low tumor-infiltrating TCRβ TRBV11.3 frequency have statistically significant longer PFS than patients with high tumor-infiltrating TCRβ TRBV11.3 frequency (p = 0.002). P was obtained using Log-Rank test. (B) Tumor-infiltrating TCRβ TRBV11.3 frequency predicts response with an AUC of 0.86. A lower tumor-infiltrating TCRβ TRBV11.3 frequency than 0.0057 have an 80% sensitivity and 85.7% specificity predicting response. (C) Patients with low tumor-infiltrating TCRβ TRBJ2.1 frequency have non-statistically significant longer PFS than patients with high tumor-infiltrating TCRβ TRBJ2.1 frequency (p = 0.051). P was obtained using Log-Rank test. (D) Tumor-infiltrating TCRβ TRBJ2.1 frequency predicts response with an AUC of 0.94. A lower tumor-infiltrating TCRβ TRBJ2.1 frequency than 0.0460 have an 100% sensitivity and 85.7% specificity predicting response. (E) Patients with low circulating TCRβ TRBJ2.6 frequency have statistically significant longer PFS than patients with high circulating TCRβ TRBJ2.6 frequency (p = 0.003). P was obtained using Log-Rank test. F) Circulating TCRβ TRBJ2.6 frequency predicts response with an AUC of 1.00. A lower circulating TCRβ TRBJ2.6 frequency than 0.0055 have an 100% sensitivity and 100% specificity predicting response. AUC: Area Under the Curve, N: number of patients, PFS: progression-free survival, *: statistical significance, **: strongly statistically significant.
